Organogenesis Holdings (ORGO) Income towards Parent Company (2016 - 2026)
Organogenesis Holdings' (ORGO) quarterly Income towards Parent Company came in at -$53.2 million in Q1 2026, down 182.1% year-on-year from $64.7 million in Q1 2025, and down 208.25% quarter-over-quarter from $49.1 million in Q4 2025.
Organogenesis Holdings (ORGO) Income towards Parent Company (2016 - 2026) Analysis & Trends
Organogenesis Holdings' Income towards Parent Company history runs 11 years deep, the most recent figure standing at -$53.2 million for Q1 2026.
- On a quarterly basis, Income towards Parent Company fell 182.1% year-over-year to -$53.2 million in Q1 2026; TTM through Mar 2026 was $8.1 million, a 151.15% increase from a year earlier, with the FY2025 full-year figure at $42.4 million, up 4828.8% from the prior year.
- Income towards Parent Company eased to -$53.2 million in Q1 2026 per ORGO's latest filing, from $49.1 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $49.1 million in Q4 2025 and bottomed at -$53.2 million in Q1 2026.
- The 5-year median for Income towards Parent Company is $1.4 million (2023), against an average of $743058.8.
- Across the five-year window, Income towards Parent Company jumped 1373.02% in 2023 and plunged 797.29% in 2025, its largest moves.
- Year by year, Income towards Parent Company stood at $7.5 million in 2022, then sank by 80.71% to $1.4 million in 2023, then jumped by 431.37% to $7.7 million in 2024, then surged by 539.97% to $49.1 million in 2025, then slumped by 208.25% to -$53.2 million in 2026.
- Per Business Quant, the three latest ORGO Income towards Parent Company figures stand at -$53.2 million (Q1 2026), $49.1 million (Q4 2025), and $21.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Organogenesis Holdings | 323.97 Mn | 231.87 Mn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.16 Mn |
| Dec 31, 2025 | 49.11 Mn |
| Sep 30, 2025 | 21.57 Mn |
| Jun 30, 2025 | -9.39 Mn |
| Mar 31, 2025 | -18.84 Mn |
| Dec 31, 2024 | 7.67 Mn |
| Sep 30, 2024 | 12.33 Mn |
| Jun 30, 2024 | -17.04 Mn |
| Mar 31, 2024 | -2.10 Mn |
| Dec 31, 2023 | 1.44 Mn |
| Sep 30, 2023 | 3.17 Mn |
| Jun 30, 2023 | 5.32 Mn |
| Mar 31, 2023 | -2.97 Mn |
| Dec 31, 2022 | 7.49 Mn |
| Sep 30, 2022 | 215,000.00 |
| Jun 30, 2022 | 8.74 Mn |
| Mar 31, 2022 | -913,000.00 |
| Dec 31, 2021 | 19.02 Mn |
| Sep 30, 2021 | 12.58 Mn |
| Jun 30, 2021 | 20.69 Mn |